Around the same time, Burwick and Feinberg (88) were the first to show that C5 blockade with eculizumab could also be used effectively to treat preeclampsia and HELLP syndrome, consistent with the protective effects seen with soluble CR1 and C5a antagonism in animal models. The gene discussed is C5; the disease is HELLP syndrome.